SCHEMBL452184

SCHEMBL452184

COC(=O)c1cc(O)c(N)c(-c2ccc(F)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.49
SLC6A4 P31645 1/20 0.49
SLC6A3 Q01959 1/20 0.49
KDM4E B2RXH2 3/20 0.47
XDH P47989 2/20 0.47
RELA Q04206 2/20 0.47
LMNA P02545 2/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
NFKB1 P19838 1/20 0.47
GFER P55789 1/20 0.47
NFKB2 Q00653 1/20 0.47
FUT7 Q11130 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
IKBKB O14920 3/20 0.47
EGFR P00533 1/20 0.46
PTGS2 P35354 1/20 0.45
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL452451 0.87 KDM4E (0.52) PTGS1SLC6A4SLC6A3KDM4ERELA
SCHEMBL443609 0.85 EGFR (0.58) KDM4EXDHRELALMNAPOLB
SCHEMBL453476 0.83 KDM4E (0.51) PTGS1SLC6A4SLC6A3KDM4EXDH
SCHEMBL4423037 0.82 EGFR (0.61) PTGS1SLC6A4SLC6A3KDM4EXDH
SCHEMBL451654 0.82 BCL2L1 (0.50) PTGS1KDM4ERELALMNAPOLB
SCHEMBL454241 0.80 VCAM1 (0.45) PTGS1SLC6A4SLC6A3KDM4ELMNA
SCHEMBL12825049 0.78 KDM4E (0.69) KDM4EXDHRELALMNAPOLB
SCHEMBL15436238 0.77 IKBKB (0.43) PTGS1SLC6A4SLC6A3KDM4ELMNA
SCHEMBL4533112 0.77 MAPK14 (0.48) SLC6A3KDM4EXDHRELALMNA
SCHEMBL462011 0.76 FPR2 (0.44) PTGS1SLC6A4SLC6A3KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238647-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2016-01-19 US disclosed
EP-2410857-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2014-01-29 EP disclosed
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain MERCK SHARP & DOHME LLC 2012-03-15 US disclosed
EP-2410857-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2012-02-01 EP disclosed
WO-2010111058-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain P2RX3, P2RX1, P2RX2 PTGS1 294/4885SLC6A4 603/4885SLC6A3 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.